Merck wins first FDA OK for diabetes-statin pill combo
This article was originally published in Scrip
Executive Summary
With the US FDA's OK of Juvisync (sitagliptin and simvastatin) on 7 October, Merck became the first company in the US permitted to sell a drug that combines a Type II diabetes medicine with a cholesterol-lowering agent into one once-daily pill.